Untreated Metastatic EGFR-Positive Non-Small Cell Lung Cancer (NSCLC) Archives

Eli Lilly’s Cyramza Passes FDA Advisory Hurdle for NSCLC

EGFR Mutations, Lancet Oncology, Non-Small Cell Lung Cancer (NSCLC), Oncologic Drugs Advisory Committee (ODAC), Untreated Metastatic EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)

Indianapolis-based Eli Lilly announced the FDA’s Oncologic Drugs Advisory Committee voted 6-5 in favor of Cyramza (ramucirumab) plus erlotinib as a potential treatment for patients with untreated metastatic EGFR-positive non-small cell lung cancer (NSCLC).

February 27, 2020/by BioSpace